Strides Pharma Q1 FY27 Earnings Call — Analysis (NSE: STAR)
Strides Pharma starts FY27 with 13% YoY revenue growth and 18.2% EBITDA margin despite geopolitical headwinds; reaffirms $375M North America aspiration by FY28 with H2 pickup expected.
The take
Q1FY27 Revenue ₹1,265 Cr ( +13% YoY ) . New guidance — FY28 north america revenue $375 million .
Results
Revenue ₹1,265 Cr +13% YoY; gross margin 60.9% (+60 bps); EBITDA margin 18.2% (-130 bps YoY, +10 bps QoQ); reported PAT ₹165.5 Cr +56.7% YoY including one-time gain from Pivot Path sale.
Financial highlights
| Metric | Value | Change | Basis |
|---|---|---|---|
| Revenue | ₹1,265 Cr | +13% | yoy · Q1FY27 |
| Gross Margin | 60.9% | +60 bps | yoy · Q1FY27 |
| EBITDA | ₹229.8 Cr | +5.4% | yoy · Q1FY27 |
| EBITDA Margin | 18.2% | -130 bps | yoy · Q1FY27 |
| Operational PAT | ₹123.1 Cr | +8% | yoy · Q1FY27 |
| Reported PAT | ₹165.5 Cr | +56.7% | yoy · Q1FY27 |
| Net Debt | ₹1,424.6 Cr | −₹11.9 Cr | sequential · Q1FY27 · vs FY26 end |
Guidance
Management reaffirms $375M North America target by FY28, expects Ex-US to grow faster than company average, guides gross margins at 58-60%, and flags H2 FY27 as stronger on new US launches and approvals.
What management committed to
- The North America business will reach a revenue of $375 million by FY28. — $375 million, FY28
- Ex-US business will grow faster than the company average over the foreseeable future. — foreseeable future
- Strides will launch 10 products in the US by March 31, 2027. — 10, FY27
- The first nasal spray ANDA will receive FDA approval in H2 FY27. — FY27
- Gross margins will remain in the 58-60% range going forward. — 58-60%, ongoing
- The Sandoz acquisition will close in Q2 FY27 and contribute revenue from H2 FY27. — FY27
- Group capex (including R&D) will be ₹250-300 Crore per annum. — ₹250-300 Cr, FY27
- Net debt will be 'fairly neutral' in 2-3 years.
Key themes
Diversification delivering, controlled substances ramp awaited
Operational commentary
- Ex-US revenue grew 17% YoY to ₹587.5 Cr ($63M); supply chain disruptions caused shipment delays of ~$7M vs Q4, expected to recover over coming quarters.
- US revenue stable at ₹628.2 Cr ($68M); launched 2 products, portfolio now 72 products; top-3 positions in 37 products contributing 70% of US sales.
- Controlled substances: completed ~20 months of sales history demonstration; awaiting response from June quota cycle; expect higher quota allocation to drive growth from next cycle.
- Nasal spray ANDA 1: under advanced FDA review, approval expected H2 FY27; ANDA 2 recently filed (12-15 month review); third filing planned in next few months.
- Niche platforms (nasal sprays, transdermal patches, thin films) in active development with multiple programs; expected to drive growth beyond $375M target.
- Chestnut Ridge (US) facility now supplies one-third of US revenue; all niche growth platforms being built around this site, increasing US manufacturing share.
- US FDA inspected Bangalore plant in May 2026; company submitted response, expects reply by Aug/Sep 2026; no impact on current supplies or growth aspirations.
- Sandoz acquisition expected to close in Q2 FY27, with revenue contribution from H2.
- Group capex (including R&D) guidance ₹250-300 Cr/year; no greenfield projects.
- CARE Ratings upgraded long-term bank facilities to CARE A+/Stable.
Analyst Q&A
Q. US business softness and path to $375M target by FY28
Five levers identified: controlled substances, new channels/geographies, product launches, OTC. H2 FY27 to see bulk of launches; confident in reaching $375M aspiration.
Q. Reason for sequential drop in Ex-US revenue to $63M from $70M and Sandoz acquisition timeline
$7M spillover due to shipment delays from geopolitical/logistics issues; will be recovered in coming quarters. Sandoz close expected in Q2 FY27, adding revenue from H2.
Q. Number and revenue potential of upcoming product launches
~10 launches targeted by March 31, 2027. Multiple levers to bridge $285M to $375M; did not quantify individual launch size.
Q. Controlled substances quota process and reasons for delays
Quota allocations twice a year (June/Dec), based on past sales history. Demonstrated 1.5 years; expect higher quota from next cycle. Controlled substances currently ~5% of revenue.
Research and educational content only. Not investment advice.